Literature DB >> 23695446

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis.

Charlotte Teunissen1, Til Menge, Ayse Altintas, José C Álvarez-Cermeño, Antonio Bertolotto, Frode S Berven, Lou Brundin, Manuel Comabella, Matilde Degn, Florian Deisenhammer, Franz Fazekas, Diego Franciotta, Jette L Frederiksen, Daniela Galimberti, Sharmilee Gnanapavan, Harald Hegen, Bernhard Hemmer, Rogier Hintzen, Steve Hughes, Ellen Iacobaeus, Ann C Kroksveen, Jens Kuhle, John Richert, Hayrettin Tumani, Luisa M Villar, Jelena Drulovic, Irena Dujmovic, Michael Khalil, Ales Bartos.   

Abstract

The choice of appropriate control group(s) is critical in cerebrospinal fluid (CSF) biomarker research in multiple sclerosis (MS). There is a lack of definitions and nomenclature of different control groups and a rationalized application of different control groups. We here propose consensus definitions and nomenclature for the following groups: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease controls (INDCs), peripheral inflammatory neurological disease controls (PINDCs), non-inflammatory neurological controls (NINDCs), symptomatic controls (SCs). Furthermore, we discuss the application of these control groups in specific study designs, such as for diagnostic biomarker studies, prognostic biomarker studies and therapeutic response studies. Application of these uniform definitions will lead to better comparability of biomarker studies and optimal use of available resources. This will lead to improved quality of CSF biomarker research in MS and related disorders.

Entities:  

Keywords:  Biomarkers; cerebrospinal fluid; control groups; study design

Mesh:

Substances:

Year:  2013        PMID: 23695446     DOI: 10.1177/1352458513488232

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  46 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Authors:  Astrid Guldbrandsen; Yehia Farag; Ann Cathrine Kroksveen; Eystein Oveland; Ragnhild R Lereim; Jill A Opsahl; Kjell-Morten Myhr; Frode S Berven; Harald Barsnes
Journal:  Mol Cell Proteomics       Date:  2016-11-27       Impact factor: 5.911

4.  Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.

Authors:  E Rodríguez-Martín; C Picón; L Costa-Frossard; R Alenda; S Sainz de la Maza; E Roldán; M Espiño; L M Villar; J C Álvarez-Cermeño
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables.

Authors:  Simona Vuletic; Hal Kennedy; John J Albers; Joep Killestein; Hugo Vrenken; Dieter Lütjohann; Charlotte E Teunissen
Journal:  Mult Scler Relat Disord       Date:  2014-07-01       Impact factor: 4.339

Review 6.  Precision medicine in myasthenia graves: begin from the data precision.

Authors:  Hai-Feng Li; Yu Hong; Yanchen Xie; Hong-Jun Hao; Ren-Cheng Sun
Journal:  Ann Transl Med       Date:  2016-03

7.  Prevalence of human Herpesviridae in cerebrospinal fluid of patients with multiple sclerosis and noninfectious neurological disease in the Netherlands.

Authors:  Gijsbert P van Nierop; Rogier Q Hintzen; Georges M G M Verjans
Journal:  J Neurovirol       Date:  2014-03-27       Impact factor: 2.643

Review 8.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

9.  Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.

Authors:  Steffen Halbgebauer; André Huss; Mathias Buttmann; Petra Steinacker; Patrick Oeckl; Isabel Brecht; Andreas Weishaupt; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

10.  Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases.

Authors:  M C Kowarik; V Grummel; S Wemlinger; D Buck; M S Weber; A Berthele; B Hemmer
Journal:  J Neurol       Date:  2013-10-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.